Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

Candel Therapeutics announced positive survival data from a phase 2a trial of CAN-2409 in NSCLC patients inadequately responding to ICI treatment.